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ABSTRACT
Introduction: Cytotoxic CD8? T-cell
lymphomas are only rarely encountered and
thus remain only poorly characterized. Our aim
was to collect and correlate clinical and
histological data of CD8? skin lymphoma
infiltrates to obtain a proper subtype
assignment of CD8? skin lymphoma
infiltrates and to derive putative prognostic
markers thereof.
Methods: Formalin-fixed and
paraffin-embedded (FFPE) tissue of 35 patients
with CD8? cytotoxic cutaneous T-cell
lymphoma infiltrates was retrieved from the
archives of the Institute of Pathology and the
Department of Dermatology, University
Hospital Wuerzburg, dating back from 1998
until 2015. Cytological, histological,
immunohistochemical and molecular genetic
features were assessed and correlated with
respective clinical data.
Results: The identified cases of CD8? cytotoxic
atypical lymphoproliferative infiltrates of the
skin (n = 35) comprised 13 cases of mycosis
fungoides (MF)/Se´zary syndrome (SS), 4 cases of
subcutaneous panniculitis-like T-cell
lymphoma (SPTCL), 5 cases of primary
cutaneous acral CD8? lymphoma [formerly
indolent CD8? lymphoid proliferation (ILP)]
and 1 case of aggressive epidermotropic primary
cutaneous T-cell lymphoma (AECTCL).
Moreover, nine cases were classified as primary
cutaneous peripheral T-cell lymphoma, not
otherwise specified (PTCL-NOS) and three
cases as systemic PTCL-NOS. Multiple skin
lesions, a high proliferative index and
especially a final subtype attribution to
AECTCL or systemic PTCL-NOS were
associated with a worse survival. Coexpression
of CD68 by tumor cells was exclusively observed
in indolent acral CD8? T-cell lymphoma and
thus indicated an invariably benign clinical
course. No further distinctive markers could be
derived from our analysis.
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Conclusion: Cutaneous infiltrates of CD8?
cytotoxic T-cell lymphoma comprise clinically
and histologically heterogeneous entities of
either primary cutaneous T-cell lymphomas or
secondary infiltrates of otherwise systemic
peripheral T-cell lymphomas. A thorough
clinicopathological correlation with respective
staging examinations remains the mainstay for
correct subtype assignment and proper
prognostication as long as no better markers
have been defined.
Keywords: Cutaneous lymphomas; Cytotoxic;
Histology; Prognosis
INTRODUCTION
Primary cutaneous T-cell lymphomas comprise
heterogeneous entities with diverse histological,
phenotypic and molecular genetic features
dependent on the respective cell of origin [1].
Most T-cell lymphomas of the skin exhibit a
skin-homing CD4? T-helper cell phenotype.
CD8? cutaneous lymphomas usually represent
rare CD8? variants of otherwise common and
well-characterized CD4? lymphomas, such as
CD8? variants of mycosis fungoides (MF) and
Se´zary syndrome (SS), CD30?
lymphoproliferative disorders, subcutaneous
panniculitis-like T-cell lymphoma (SPTCL) or
peripheral T-cell lymphoma, not otherwise
specified (PTCL-NOS) [2]. In contrast, an
exclusive CD8? phenotype is present in the
eponymous CD8? acral T-cell lymphoma [3]
formally known as CD8? indolent lymphoid
proliferation (ILP) [4] as well as in aggressive
epidermotropic cutaneous T-cell lymphoma
(AECTCL) [5].
Such rare CD8? cytotoxic cutaneous
lymphomas often confront the
dermatopathologist with intricate diagnostic
workup and, moreover, may represent a
therapeutic dilemma for the treating
dermatologist. We therefore systematically
collected all appropriately recorded CD8?
cytotoxic lymphoma infiltrates of the skin
being encountered at our institution, spanning
a time period of more than 15 years. Our
intention was to better characterize such CD8?
lymphoma infiltrates based on histological,
immunophenotypical and clinical grounds, and
ultimately we tried to provide a better subtype
attribution and to delineate putative diagnostic
and/or prognostic markers to guide the patient
management of this rare lymphoma variant.
METHODS
Formalin-fixed and paraffin-embedded (FFPE)
tissue of patients with EBV-negative cutaneous
CD8? cytotoxic cutaneous T-cell lymphoma
infiltrates was retrieved from the archives of the
Institute of Pathology, University of Wuerzburg,
and the Department of Dermatology, University
Hospital Wuerzburg, dating back from 1998
until 2015. Only cases with sufficient analyzable
FFPE tissue and corresponding clinical data were
included for further analysis. The final diagnosis
of lymphoma with subtype assignment was
based on a compatible histomorphology,
immunophenotype and clonal T-cell receptor
gene rearrangement in close correlation with
the medical history and clinical presentation
according to the current World Health
Organization (WHO)/European Organization
for Research and Treatment of Cancer
(EORTC) classification [1] taking account of
the revised WHO proposal [3].
Immunohistochemical studies were performed
on FFPE tissue sections using the
avidin–biotin-peroxidase complex method and
stained in an autostainer in the case of the
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routine antibody panel and manually for
selected remaining antibodies, such as PIM1,
VEGFR2 and PDGFRa. Polymerase chain
reaction (PCR) analysis of the TCR-c gene was
performed on DNA extracted from FFPE tissue
according to the previously published protocol
of the Biomed-2 guidelines. Statistical analysis
of histological and clinical data was performed
with the SPSS software version 22 (IBM GmbH,
Germany).
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study and for
publication of the patient photographs.
RESULTS
During a 17-year time period, 35 cases could be
identified that fulfilled our inclusion criteria;
more than 30 cases had to be excluded because
of lack of adequate tissue and/or clinical data.
Clinicopathological correlation yielded the
diagnosis of MF/SS in 13 cases, SPTCL in 4
cases, CD8? acral lymphoma in 5 cases and
AECTCL in 1 case. Moreover, 9 out of 35 cases
were classified as primary cutaneous PTCL-NOS,
while secondary lymphoma infiltrates of the
skin due to underlying systemic PTCL-NOS were
encountered in 3 cases. Detailed clinical patient
characteristics are summarized in Table 1 and
histological and immunophenotypic findings
in Tables 2 and 3, respectively. Survival data are
shown in Fig. 1a.
With respect to CD8? MF, atypical clinical
features mimicking cutaneous mastocytosis or
purpura pigmentosa (Fig. 2a) and pityriasis alba
(Fig. 2b) commonly diverted the clinician from
a prompt initial diagnosis. The corresponding
histological pattern was otherwise rather similar
to classical CD4? MF (Fig. 2c,d). Mean overall
survival of patients with CD8? MF was
56 months with a corresponding wide range of
12 to 159 months depending on the lymphoma
stage. The patients with CD8? MF showed a
clinical course quite similar to otherwise
encountered CD4? variants; one of these
patients died because of progressive lymphoma
after 12 months.
CD8? lymphomas (n = 21) with deep
(dermal or subcutaneous) infiltrates mainly
comprised rare and hitherto provisional
entities designated as lymphoma subtypes.
Five of these cases belonged to the provisional
entity of acral CD8? T-cell lymphoma (ILP) and
invariably showed an indolent course with
unrestricted survival. The remaining 16 cases
exhibited a significantly worse survival and
were diagnosed as either primary (n = 9) or
secondary (n = 3) cutaneous PTCL-NOS or as
SPTCL (n = 4). These patients exhibited a mean
overall survival of 51 ± 66, 24 ± 17 and
27 ± 43 months, respectively. Of this subgroup
5/16 patients died of lymphoma (among these
all three patients with secondary PTCL-NOS),
whereas an additional 4/16 patients died of
other unrelated causes. All 16 of these patients
presented with either solitary/regional (n = 8;
Fig. 3a) or multiple (n = 8) tumors and/or
infiltrated plaques (Fig. 3c). Those patients
with a solitary skin lesion of their PTCL-NOS
or SPTCL had a trend to better mean overall
survival than patients with multiple skin
manifestations (61 ± 65 vs. 21 ± 23 months;
P = 0.1), albeit exhibiting a wide variation of
survival time (Fig. 1b). Solitary manifestation at
an acral site (face and finger) represented an
independent positive prognostic factor within
the patient subgroup of PTCL-NOS with an
average overall survival of 112 months. Better
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survival for patients with solitary skin
manifestation at the time of initial
presentation was not only observed for this
subgroup of deep dermal/subcutanous CD8?
lymphoma infiltrates, but was also true for all
studied cases of CD8? lymphomas: overall
survival was 74 ± 63 months for patients with
localized disease manifestation as compared to
31 ± 30 months for patients exhibiting multiple
lesions (P = 0.01).
In addition to clinical features, we were also
interested in thorough histological and
immunohistological characterization of our
selected CD8? lymphomas. Histological
features and further immunophenotypic
characterization are depicted in Tables 2 and 3.
Whereas most of the MF cases showed small-
and medium-sized neoplastic cells with rare
large-cell transformation and systemic
PTCL-NOS showed large neoplastic cells, cell
size was otherwise rather evenly distributed
among the different entities (Fig. 3b, d).
Hence, survival rates were not significantly
different between lymphomas with
predominantly small- or medium-sized cells
and lymphomas with large-cell morphology
(P = 0.6). Moreover, ulceration, angiocentricity
and adnexotropism were a common feature of
PTCL-NOS but not of indolent acral CD8?
lymphoma.
With regard to immunohistochemical
features, a high proliferation index
(ki67[60%) implied a worse mean overall
survival (P\0.05; Fig. 4a). Loss of one or
several of the T-cell antigens (CD5 and CD7),
overexpression of PIM1, PDGFRa or an activated
cytotoxic phenotype (positivity of GrB in
conjunction with variable expression of T-cell
intracellular antigen-1 [TIA] or perforin; Fig. 4b)
were not associated with a more aggressive
subtype or a worse clinical course. To note,
PIM1 expression was observed with a moderate
Table 1 Clinical characteristics of the subtypes of CD8? cytotoxic lymphomas
Age Sex Morphology of lesions Extent of lesions Duration
of lesions
(months)









n n n n n n n
Mycosis
fungoides
44 14 8 5 5 2 5 2 11 44 58
Cutaneous
PTCL
61 11 7 2 1 7 1 8 1 6 11
ILP 62 10 2 3 2 3 0 5 0 28 17
SPTCL 52 6 1 3 0 4 0 0 4 7 5
AECTCL 26 1 0 1 0 0 0 1 3
Systemic
PTCL
76 12 2 1 1 1 1 1 2 6 6
AECTCL aggressive epidermotropic primary cutaneous T-cell lymphoma, ILP acral CD8? T-cell lymphoma, formerly
indolent CD8? lymphoid proliferation, PTCL peripheral T-cell lymphoma, SD standard deviation, SPTCL subcutaneous
panniculitis-like T-cell lymphoma
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to high staining intensity in all the analyaed
lymphoma subtypes, whereas only few
lymphoma cells expressed PDGFRa. None of
the lymphomas expressed ALK, EBER, VEGFR2
or Tcl1. There was variable expression of PD1
and CD56. An aberrant expression of
immunohistochemical markers by the
neoplastic cells was rarely observed:
coexpression of CD20 by the neoplastic T-cells
of cutaneous PTCL-NOS was detected in one
case, and expression of CD68 in a dot-like
intracytoplasmic pattern was exclusively
observed in lymphoma cells of indolent acral
CD8? lymphoma.
DISCUSSION
Owing to its versatile clinical and histological
presentation, CD8? cytotoxic cutaneous
lymphomas still represent one of the major
challenges within the field of dermatology and
histopathology. While the current WHO/
EORTC classification does not allow further
subdivision within this lymphoma subgroup
based on criteria such as the extent and
localization of skin lesions, cell size or T-cell
phenotype, and comprehensive molecular
features, including gene expression data or
mutation profiles are still lacking, a plethora
of clinical and histopathological features has up
to now been collected and proposed to portend
a putative prognostic impact. These include
cytomorphology (small versus large cells),
immunophenotype (loss or presence of T-cell
antigens: CD2, CD5 and CD7 [6, 7]), expression
of T-cell receptor a/b-chains versus T-cell
receptor c/ë-chains [8], expression of cytotoxic
proteins [perforin, granzyme B (GrB), T-cell
intracellular antigen (TIA)] [9], proliferative
activity (ki67) [9]), architectural features of the
infiltrate (epidermotropism, depth of infiltrate
and angioinvasion) and clinical presentation
[solitary versus multiple lesions corresponding
to tumor stage according to the EORTC-/
Fig. 1 Overall survival of all analyzed CD8? lymphoma
subtypes and overall survival according to extent of skin
lesions. a Overall survival of the different subtypes of
CD8? cytotoxic cutaneous lymphomas shows large
heterogeneity with unrestricted survival in ILP up to
highly limited survival in AECTL and systemic
PTCL-NOS. b Overall survival of patients presenting
with solitary/localized skin lesions is signiﬁcantly higher
than the overall survival of patients with multiple lesions
(74 ± 63 vs. 31 ± 30 months for patients; P = 0.01),
albeit showing wide variation. AECTCL aggressive
epidermotropic primary cutaneous T-cell lymphoma,
ILPacral CD8? T-cell lymphoma, formerly indolent
CD8? lymphoid proliferation, NOS not otherwise
speciﬁed, PTCL peripheral T-cell lymphoma, SPTCL
subcutaneous panniculitis-like T-cell lymphoma
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ISCL-classification (TNM) or the International
Prognostic Index (IPI)/Peripheral T-cell
Lymphoma Index (PTI) score].
While in our analysis most of the cases of MF
presented with small lymphoma cells, large
tumor cells with partly blast-like morphology
were prevailing in both primary cutaneous and
secondary cutaneous PTCL-NOS. With respect
to MF, large-cell transformation has been
established as an independent negative
prognostic factor, irrespective of age, tumor
stage and IPI score and independent of
concomitant CD30 expression [10]. In one of
the largest recent studies addressing the
predictive impact of cytology in 82 patients
with cutaneous cytotoxic PTCL-NOS, small-/
medium-sized cell type turned out to have
prognostic impact [11]. However, divergent
from our approach, both CD4? and CD8?
PTCL-NOS presenting with a cytotoxic
phenotype were included in this analysis, and
the favorable subgroup of small-/medium-sized
lymphomas was mainly attributed to CD4?
small-/medium-sized pleomorphic T-cell
Fig. 2 Selected clinical and histological examples of
atypical presentation of CD8?MF cases. CD8? cytotoxic
MF frequently exhibits atypical clinical presentation
mimicking mastocytosis (urticaria pigmentosa) a in the
case of hyperpigmented and purpuric MF or pityriasis
alba/vitiligo and b in hypopigmented juvenile MF.
c Histology of case (a) shows an atypical band-like
inﬁltrate of pleomorphic small-/medium-sized lymphocytes
with frank epidermotropism in a pagetoid pattern together
with interface dermatitis, dermal erythrocytes, melanophages
and hemosiderophages. Dermal and epidermal lymphoma
cells of case (a) strongly express CD8 (d) and cytotoxic
molecules. MF mycosis fungoides
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lymphoma (SMPTCL) with a well-known
indolent behavior [12].
Extent of skin lesions is one of the major
categories within the IPI for predicting the
biological behavior of systemic PTCL and
accordingly directing further therapeutic
approaches [11]. Solitary skin lesions were
attributed to a longer overall survival in our 35
cases of CD8? cytotoxic lymphomas.
A recent study highlighted the negative
prognostic impact of both c/ë-T-cell receptor
expression (Vë1 subset) and deep subcutaneous
involvement in cutaneous T-cell lymphoma
[11]. However, rare expression of c/ë-T-cell
receptor chains may also be observed in CD4?
or CD8? cutaneous lymphomas, such as MF,
anaplastic large-cell lymphoma or pagetoid
reticulosis, and these lymphomas run a rather
Fig. 3 Representative clinical and histological examples of
cutaneous PTCL-NOS. Localized skin lesions at time of
diagnosis of primary cutaneous PTCL-NOS a exhibiting a
highly epidermotropic lymphoma inﬁltrate of highly
proliferating pleomorphic small-/medium-sized lymphoma
cells (b). c Multiple disseminated non-ulcerated patches,
plaques and ﬂat tumors at the trunk and extremities are
present in this patient with cutaneous PTCL-NOS.
d Histology shows blast-like large dermal tumor cells with
multiple mitotic ﬁgures. PTCL-NOS peripheral T-cell
lymphoma, not otherwise speciﬁed
206 Oncol Ther (2016) 4:199–210
indolent or stage-dependent course [13]. In less
than 1% of cases, lineage infidelity with, e.g.,
aberrant expression of CD20 or concomitant
dual expression of both c/ë-chains and
ab-chains of the T-cell receptor [14] may be
observed, as was present in one case of
cutaneous PTCL-NOS in our study.
With regard to T-cell antigen expression, it
has been initially postulated that loss of several
T-cell markers, such as CD2 and CD5, could
serve as a diagnostic clue for AECTCL and thus
portend a worse prognosis [6, 7]. However, more
recent studies, including ours, showed more
variable and inconsistent expression (or loss) of
the T-cell antigens CD2, CD5 and CD7 [15], so
these immunophenotypic features do not serve
as helpful diagnostic adjuncts.
Several studies on systemic CD8? (and
CD4?) PTCL-NOS have already addressed the
question whether an activated cytotoxic
phenotype might represent an adverse
prognostic factor. Most of the studies,
including a large recent analysis of 340
patients with CD4? and CD8? PTCL-NOS,
being analyzed within the International
Peripheral T-cell Lymphoma Project could
not confirm a negative prognostic impact
thereof [9, 16, 17]. However, a subgroup of
PTCL-NOS with molecular features of
cytotoxic lymphocytes exhibiting
overexpression of TBX21 while being
negative for GATA3 was recently identified
to portend a worse prognosis [18]. In our
analysis on cutaneous lymphomas, an
activated cytotoxic phenotype did not
harbor any prognostic impact. Of note, being
in line with most of the previously reported
results in systemic PTCL-NOS [19], a high
proliferation index (ki67[60%) indicated a
worse survival in our cohort. On the other
hand, we have recently shown that low
proliferative capacity together with an
exclusive expression of CD68 in a particular
dot-like pattern in the lymphoma cells
represents a unique hallmark of primary
cutaneous acral CD8? T-cell lymphoma and
thus presents an indolent behavior when
present [20].
Fig. 4 Overall survival with respect to proliferation rate
and cytotoxic phenotype. a Overall survival for patients
showing a high proliferation rate as assessed by [60%
ki67-positive lymphoma cells is signiﬁcantly lower than
low-proliferating tumors (P\0.05). b Presence of an
activated cytotoxic phenotype [positivity of GrB together
with perforin and/or T-cell intracellular antigen (TIA)]
does not affect overall survival
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With the aim to gain further insight into the
pathogenesis and the biological behavior of rare
cutaneous lymphomas, such as CD8? cytotoxic
lymphomas, much can be learned and
transferred from recent work on molecular
profiling of systemic PTCL-NOS, including
gene expression and deep sequencing analysis
[19, 21, 22]. Gene expression profiling has once
again confirmed that within the generic term of
systemic PTCL-NOS, there is extensive
molecular heterogeneity as already evidenced
by divergent clinical, histological and
immunophenotypical data [18, 23, 24].
Moreover, taking the limited therapeutic
opportunities and the often dismal prognosis
of PTCL-NOS into consideration, the progress in
deciphering the mutational landscape and the
subtype-specific gene expression profiles has
revealed several novel therapeutic options [25].
Putative targets include the network of
epigenetic modifiers [26] as well as the NFjB,
STAT and JAK pathways [27], PIM kinases [27]
and downstream signaling of tyrosine receptors,
such as PDGFRa [28] and VEGFR [29]. In the
lymphoma cases presented here, the expression
pattern of PIM1 (which was actually present in
almost all cases), VEGFR or PDGFRa (which
were almost altogether absent in our cohort) did
not serve as putative prognostic markers, so that
these data could not be recapitulated in our
CD8? cutaneous lymphoma cohort.
CONCLUSIONS
Our retrospective analysis once again underlines
that when dealing with CD8? cutaneous
lymphoma, the crucial approach still remains to
unify the histological and clinical data to make a
correct diagnosis with prognostically relevant
subtype attribution as long as better
immunophenotypical and especially genetic
data are still lacking. In the future, molecular
profiling of such rare lymphoma variants will
hopefully contribute to ameliorate treatment
strategies as a result of more precise subtype
definition and to develop more individualized
treatment strategies, including targeted
therapies. As cutaneous CD8? lymphomas
represent rare entities and our study data are
therefore limited in its conclusions, a broader
multi-institutional approach for these lymphoma
entities is urgently warranted in the future.
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